Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 407 results
Filters: Keyword is Male  [Clear All Filters]
Found 407 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

E

Sax PE, Sloan CE, Schackman BR, et al. "Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164." HIV Clin Trials. 2010;11(5):248-59.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Marc LG, Testa MA, Walker AM, et al. "Educational attainment and response to HAART during initial therapy for HIV-1 infection." J Psychosom Res. 2007;63(2):207-16.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Geng EH, Kahn JS, Chang OC, et al. "The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation." Clin. Infect. Dis.. 2011;53(10):1008-14.
Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. "Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy." HIV Clin Trials. 2007;8(6):429-36.
Gandhi RT, Spritzler J, Chan E, et al. "Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384." J. Acquir. Immune Defic. Syndr.. 2006;42(4):426-34.
Acosta EP, Kendall MA, Gerber JG, et al. "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily." Antimicrob. Agents Chemother.. 2007;51(9):3104-10.
Ribaudo HJ, Liu H, Schwab M, et al. "Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study." J. Infect. Dis.. 2010;202(5):717-22.
Kitahata MM, Gange SJ, Abraham AG, et al. "Effect of early versus deferred antiretroviral therapy for HIV on survival." N. Engl. J. Med.. 2009;360(18):1815-26.
Iii HLTwigg, Weiden M, Valentine F, et al. "Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects." J. Infect. Dis.. 2008;197(1):109-16.
Bar KJ, Sneller MC, Harrison LJ, et al. "Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption." N. Engl. J. Med.. 2016;375(21):2037-2050.
Velilla PA, Shata MT, Lages CS, Ying J, Fichtenbaum CJ, Chougnet C. "Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients." AIDS Res. Hum. Retroviruses. 2008;24(1):52-61.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
Gandhi RT, Zheng L, Bosch RJ, et al. "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial." PLoS Med.. 2010;7(8).
Hennig S, Naiker S, Reddy T, et al. "Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis." Antimicrob. Agents Chemother.. 2015;60(1):617-20.
Overton ET, Kitch D, Benson CA, et al. "Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death." Clin. Infect. Dis.. 2013;56(10):1471-9.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Nixon DE, Bosch RJ, Chan ES, et al. "Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5." J Clin Lipidol. 2017;11(1):61-69.
Smurzynski M, Wu K, Letendre S, et al. "Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort." AIDS. 2011;25(3):357-65.
Blackard JT, Kang M, Sherman KE, Koziel MJames, Peters MG, Chung RT. "Effects of HCV treatment on cytokine expression during HCV/HIV coinfection." J. Interferon Cytokine Res.. 2006;26(11):834-8.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.

Pages